The Value of Moderna's mRNA Technology Is Obscured by Fears of a Hostile US Regulatory Environment
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
GSK resolves patent lawsuit against Pfizer over RSV vaccines
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
GlaxoSmithKline (GSK) Receives a Buy from Bernstein
In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs
Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
GSK Pharma call volume above normal and directionally bullish
Bullish option flow detected in GSK (GSK) Pharma with 5,714 calls trading, 4x expected, and implied vol increasing over 5 points to 42.48%. Apr-25 38 calls and 4/4 weekly 37 puts are the most active ...
American Association of Individual Investors2d
Which Is a Better Investment, Corcept Therapeutics Incorporated or GSK plc Stock?
Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...
Is GSK plc (GSK) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other most ...
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...